<DOC>
	<DOCNO>NCT01586052</DOCNO>
	<brief_summary>This purpose phase 1 study investigate safety efficacy erythropoetin child cerebral palsy .</brief_summary>
	<brief_title>Erythropoietin Therapy Children With Cerebral Palsy : Phase 1</brief_title>
	<detailed_description>Cerebral palsy disorder movement posture result nonprogressive lesion injury immature brain . It lead cause childhood onset disability . Many experimental animal study reveal erythropoietin useful repair neurological injury brain . The main mechanism erythropoietin suppose follow ; neuroprotection effect , angiogenesis , anti-inflammation . On basis many experimental study , erythropoietin suggest potential therapy cerebral palsy .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Cerebral Palsy Abnormal Muscle Tone GMFCS ( Gross Motor Functional Classification System ) : II IV Age : 6 month ~ 3 year Abnormal Brain MRI compatible clinical feature nonprogressive Willing Comply All Study Procedure Known Genetic Disorder Baseline Erythropoietin level &gt; 45 mU/mL Presence Drug Hypersensitivity Related Study Remedy Previous Erythropoietin Treatment 3 month Coagulopathy : Family History , Unknown Cerebral Infarction , Thromboembolic Events History Intractable Seizure Disorder Poor Cooperation Guardian include Inactive Attitude Rehabilitation Uncontrolled Hypertension Liver Dysfunction Renal Dysfunction Absolute Neutrophil Count &lt; 500/dL Intracerebral Intraventricular Hemorrhage Malignancy</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Cerebral Palsy</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Rehabilitation</keyword>
</DOC>